These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 24582749)

  • 21. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
    Tang X; Jiang J; Zhu J; He N; Tan J
    Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
    Chen JC; Su YH; Chiu CF; Chang YW; Yu YH; Tseng CF; Chen HA; Su JL
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S555-63. PubMed ID: 24723223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
    Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
    Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
    Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
    J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
    Zhou YM; Liu J; Sun W
    Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
    Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
    J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
    Ge X; Zheng L; Huang M; Wang Y; Bi F
    Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
    Fan D; Yang Y; Zhang W
    BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer.
    Zhang Y; Qian J; Fu Y; Wang Z; Hu W; Zhang J; Wang Y; Guo Y; Chen W; Zhang Y; Wang X; Xie Z; Ye H; Ye F; Zuo Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167447. PubMed ID: 39089636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
    Wang N; Zhang T
    Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
    Niu R; Li D; Chen J; Zhao W
    Cell Cycle; 2022 Jan; 21(1):86-100. PubMed ID: 34919024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
    Pang W; Tian X; Bai F; Han R; Wang J; Shen H; Zhang X; Liu Y; Yan X; Jiang F; Xing L
    Mol Cancer; 2014 Oct; 13():240. PubMed ID: 25342548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
    Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.